Arbutus Biopharma (ABUS) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Arbutus Biopharma is set to present at the Jefferies London Healthcare Conference to discuss its innovative approaches in treating chronic hepatitis B virus. The company’s pipeline includes promising treatments like the RNAi therapeutic imdusiran and an oral PD-L1 inhibitor, which are in crucial stages of clinical trials.
For further insights into ABUS stock, check out TipRanks’ Stock Analysis page.
